Pharmaceuticals

A major factor driving the Next Generation Antibody Drug Market is the increasing adoption of personalized medicine supported by advancements in genomic sequencing

March 23, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Next Generation Antibody Drug Market During The Forecast Period 2026–2030?

The next generation antibody drug market has seen rapid expansion recently. This market is projected to expand from $16.4 billion in 2025 to $18.93 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.4%. Historically, this increase can be linked to the achievements of monoclonal antibody treatments, an increase in cancer cases, progress in antibody engineering, greater investment in biologics research and development, and the authorization of new antibody medications.

The next generation antibody drug market size is projected to experience substantial growth in the upcoming years. It is anticipated to expand to $33.53 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.4%. This expansion during the forecast period can be linked to several factors, including the increasing adoption of precision medicine, a heightened demand for targeted biologics, continuous advancements in conjugation technologies, the broadened scope of autoimmune disease treatments, and a burgeoning pipeline of oncology drugs. Significant trends expected in this period encompass the rapid advancement of bispecific antibodies, the growing uptake of antibody-drug conjugates, an intensified focus on precision targeted therapies, the diversification of antibody applications beyond oncology, and a rise in clinical trials for advanced antibody platforms.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24335&type=smp

What Drivers Are Expected To Influence The Next Generation Antibody Drug Market During The Forecast Period?

A growing emphasis on personalized medicine is anticipated to propel the next-generation antibody-drug market forward. Personalized medicine refers to a medical methodology that customizes treatment and healthcare strategies for individual patients based on their genetic, environmental, and lifestyle factors, leading to more effective and targeted therapies. Its rise is attributed to advancements in genomic sequencing, which allow for more precise diagnoses and tailored treatment approaches. Next-generation antibody drugs facilitate this increased focus on personalized medicine by enabling the development of targeted therapies specifically customized to individual patients’ genetic profiles and disease characteristics, thereby improving efficacy and minimizing adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based organization promoting the adoption of personalized medicine, in 2023, the United States Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients, an increase from 6 in 2022. Therefore, the expanding focus on personalized medicine significantly drives the next-generation antibody drug market.

What Market Segments Are Evaluated Within The Next Generation Antibody Drug Market?

The next generation antibody drug market covered in this report is segmented –

1) By Product Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Types

2) By Mechanism Of Action: Checkpoint Inhibitors, Immune Modulators, Receptor Blockers, Targeted Cytotoxic Agents, Neutralizing Antibodies

3) By Delivery Method: Intravenous (IV) Administration, Subcutaneous Administration, Intramuscular Administration

4) By Application: Oncology, Autoimmune Diseases, Infectious Diseases, Other Applications

5) By End User: Hospitals, Research Institutes, Specialty Clinics, Other End Users

Subsegments:

1) By Monoclonal Antibodies: Human Monoclonal Antibodies, Murine Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies

2) By Bispecific Antibodies: Checkpoint Inhibitor-Based Bispecifics, Bispecific Antibodies For Cytokine Modulation, Bispecific Antibodies With Extended Half-Life Technologies

3) By Antibody-Drug Conjugates: Cleavable Linker Antibody-Drug Conjugates, Non-Cleavable Linker Antibody-Drug Conjugates, Site-Specific Conjugated Antibody-Drug Conjugates

What Industry Trends Are Redefining The Next Generation Antibody Drug Market?

Businesses within the next generation antibody drug market are prioritizing the creation of novel approaches, including antibody-drug conjugates, to advance targeted cancer treatments, boost therapeutic effectiveness, and lessen overall toxicity. An antibody-drug conjugate (ADC) functions as a specific cancer treatment, linking a monoclonal antibody with a cytotoxic drug through a linker to precisely transport the medicine to tumor cells, thereby limiting harm to healthy tissues. As an example, January 2024 saw BioNTech SE, a biotechnology firm from Germany, collaborate with Duality Biologics (Suzhou) Co. Ltd., a pharmaceutical company based in China. This partnership led to their next-generation antibody-drug conjugate (ADC) candidate, BNT325/DB-1305, receiving a Fast Track designation from the U.S. Food and Drug Administration (FDA) for its potential treatment of platinum-resistant ovarian cancer. This particular drug leverages DualityBio’s cutting-edge DITAC (Duality Immune Toxin Antibody Conjugates) platform, which merges a powerful cytotoxic payload with a monoclonal antibody, ensuring precise delivery of the treatment directly to cancerous cells. The capacity of BNT325/DB-1305 to accurately target cancer cells while concurrently lessening harm to healthy tissues is a significant benefit, crucial for improving treatment effectiveness and lowering adverse reactions.

Who Are The Top Market Participants Influencing The Next Generation Antibody Drug Market?

Major companies operating in the next generation antibody drug market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics Co. Ltd., WuXi Biologics Inc., Akeso Inc., Xencor Inc., ImmunoGen Inc., Philogen S.p.A., Telix Pharmaceuticals Limited, Actinium Pharmaceuticals Inc.

Read the full next generation antibody drug market report here:

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-drug-global-market-report

Which Region Is Forecast To Lead The Next Generation Antibody Drug Market In Terms Of Market Size?

North America was the largest region in the next generation antibody drug market in 2025. The regions covered in the next generation antibody drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Next Generation Antibody Drug Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24335&type=smp

Browse Through More Reports Similar to the Global Next Generation Antibody Drug Market 2026, By The Business Research Company

Next Generation Antibody Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Antibody Drug Conjugates Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Antibody Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibody-discovery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795